View in EDS

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).

Saved in:
Bibliographic Details
Title: Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Authors: Turner N; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom., Saura C; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Aftimos P; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium., van den Tweel E; Byondis B.V., Nijmegen, the Netherlands., Oesterholt M; Byondis B.V., Nijmegen, the Netherlands., Koper N; Byondis B.V., Nijmegen, the Netherlands., Colleoni M; Division of Medical Senology, European Institute of Oncology, Milan, Italy., Kaczmarek E; Medical Oncology Department, Centre Oscar Lambret, Lille, France., Punie K; Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Song X; Medical Oncology, The Ottawa Hospital Cancer Center, Ottawa, ON, Canada., Armstrong A; Medical Oncology, The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom., Bianchi G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Stradella A; Department of Medical Oncology, Institut Català d'Oncologia-L'Hospitalet IDIBELL, Barcelona, Spain., Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Lim JSJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Quenel-Tueux N; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France., Tan TJ; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Escrivá-de-Romaní S; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., O'Shaughnessy J; Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.
Corporate Authors: TULIP Trial Investigators
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Feb 10; Vol. 43 (5), pp. 513-523. Date of Electronic Publication: 2024 Oct 23.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39442070
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Turner+N%22">Turner N</searchLink>; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Saura+C%22">Saura C</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Aftimos+P%22">Aftimos P</searchLink>; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22van+den+Tweel+E%22">van den Tweel E</searchLink>; Byondis B.V., Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Oesterholt+M%22">Oesterholt M</searchLink>; Byondis B.V., Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Koper+N%22">Koper N</searchLink>; Byondis B.V., Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Colleoni+M%22">Colleoni M</searchLink>; Division of Medical Senology, European Institute of Oncology, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Kaczmarek+E%22">Kaczmarek E</searchLink>; Medical Oncology Department, Centre Oscar Lambret, Lille, France.<br /><searchLink fieldCode="AU" term="%22Punie+K%22">Punie K</searchLink>; Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Song+X%22">Song X</searchLink>; Medical Oncology, The Ottawa Hospital Cancer Center, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Armstrong+A%22">Armstrong A</searchLink>; Medical Oncology, The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bianchi+G%22">Bianchi G</searchLink>; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Stradella+A%22">Stradella A</searchLink>; Department of Medical Oncology, Institut Català d'Oncologia-L'Hospitalet IDIBELL, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Ladoire+S%22">Ladoire S</searchLink>; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Lim+JSJ%22">Lim JSJ</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Quenel-Tueux+N%22">Quenel-Tueux N</searchLink>; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Tan+TJ%22">Tan TJ</searchLink>; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Escrivá-de-Romaní+S%22">Escrivá-de-Romaní S</searchLink>; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22O'Shaughnessy+J%22">O'Shaughnessy J</searchLink>; Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22TULIP+Trial+Investigators%22">TULIP Trial Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2025 Feb 10; Vol. 43 (5), pp. 513-523. <i>Date of Electronic Publication: </i>2024 Oct 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39442070
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.24.00529
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 513
    Titles:
      – TitleFull: Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Turner N
      – PersonEntity:
          Name:
            NameFull: Saura C
      – PersonEntity:
          Name:
            NameFull: Aftimos P
      – PersonEntity:
          Name:
            NameFull: van den Tweel E
      – PersonEntity:
          Name:
            NameFull: Oesterholt M
      – PersonEntity:
          Name:
            NameFull: Koper N
      – PersonEntity:
          Name:
            NameFull: Colleoni M
      – PersonEntity:
          Name:
            NameFull: Kaczmarek E
      – PersonEntity:
          Name:
            NameFull: Punie K
      – PersonEntity:
          Name:
            NameFull: Song X
      – PersonEntity:
          Name:
            NameFull: Armstrong A
      – PersonEntity:
          Name:
            NameFull: Bianchi G
      – PersonEntity:
          Name:
            NameFull: Stradella A
      – PersonEntity:
          Name:
            NameFull: Ladoire S
      – PersonEntity:
          Name:
            NameFull: Lim JSJ
      – PersonEntity:
          Name:
            NameFull: Quenel-Tueux N
      – PersonEntity:
          Name:
            NameFull: Tan TJ
      – PersonEntity:
          Name:
            NameFull: Escrivá-de-Romaní S
      – PersonEntity:
          Name:
            NameFull: O'Shaughnessy J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 02
              Text: 2025 Feb 10
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1